{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:30:21Z","timestamp":1792798221742,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012250","name":"Cooperation Program of Qinghai Province","doi-asserted-by":"publisher","award":["2022-QY-201"],"award-info":[{"award-number":["2022-QY-201"]}],"id":[{"id":"10.13039\/501100012250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060644"],"award-info":[{"award-number":["82060644"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s13346-023-01400-0","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T13:02:10Z","timestamp":1692018130000},"page":"329-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Evaluation of microstructure, dissolution rate, and oral bioavailability of paclitaxel poloxamer 188 solid dispersion"],"prefix":"10.1007","volume":"14","author":[{"given":"Yao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"issue":"6","key":"1400_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14656566.2020.1724284","volume":"21","author":"CL Della","year":"2020","unstructured":"Della CL, Barra F, Foreste V, Giampaolino P, Evangelisti G, Ferrero S, Bifulco G. Advances in paclitaxel combinations for treating cervical cancer. Expert Opin Pharmacother. 2020;21(6):663\u201377.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1400_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","volume":"32","author":"PA Fasching","year":"2021","unstructured":"Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S. Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2021;32(1):49\u201357.","journal-title":"Ann Oncol"},{"issue":"2","key":"1400_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.21873\/invivo.12376","volume":"35","author":"T Okada","year":"2021","unstructured":"Okada T, Okamoto I, Sato H, Ito T, Miyake K, Tsukahara K. Efficacy and safety of paclitaxel combined with cetuximab for head and neck squamous cell carcinoma. In Vivo. 2021;35(2):1253\u20139.","journal-title":"In Vivo"},{"key":"1400_CR4","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.2147\/IJN.S290731","volume":"16","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhang K, Zhu X, Zheng X, Wang C, Niu X, Jiang T, Ji X, Zhao W, Pang L, Qi Y, Li F, Li L, Xu Z, Gu W, Zou H. Synergistic inhibition of drug-resistant colon cancer growth with PI3K\/mTOR dual inhibitor BEZ235 and nano-emulsioned paclitaxel via reducing multidrug resistance and promoting apoptosis. Int J Nanomedicine. 2021;16:2173\u201386.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"1400_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/10408347.2017.1416283","volume":"48","author":"RC Alves","year":"2018","unstructured":"Alves RC, Fernandes RP, Eloy JO, Salgado HRN, Chorilli M. Characteristics, properties and analytical methods of paclitaxel: a review. Crit Rev Anal Chem. 2018;48(2):110\u20138.","journal-title":"Crit Rev Anal Chem"},{"issue":"4","key":"1400_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/10837450.2021.1884259","volume":"26","author":"P Tran","year":"2021","unstructured":"Tran P, Park J. Formulation of solid dispersion to improve dissolution and oral bioavailability of poorly soluble dexibuprofen. Pharm Dev Technol. 2021;26(4):422\u201330.","journal-title":"Pharm Dev Technol"},{"issue":"4","key":"1400_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/03639045.2017.1408642","volume":"44","author":"Z Vinarov","year":"2018","unstructured":"Vinarov Z, Katev V, Radeva D, Tcholakova S, Denkov ND. Micellar solubilization of poorly water-soluble drugs: effect of surfactant and solubilizate molecular structure. Drug Dev Ind Pharm. 2018;44(4):677\u201386.","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"1400_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ijpharm.2015.09.021","volume":"495","author":"J Du","year":"2015","unstructured":"Du J, Li X, Zhao H, Zhou Y, Wang L, Tian S, Wang Y. Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies. Int J Pharm. 2015;495(2):738\u201349.","journal-title":"Int J Pharm"},{"issue":"3","key":"1400_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1517\/17425247.2013.752354","volume":"10","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Mei L, Feng S. Paclitaxel drug delivery systems. Expert Opin Drug Deliv. 2013;10(3):325\u201340.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"1400_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5455\/jabet.2019.d26","volume":"2","author":"M Rahman","year":"2019","unstructured":"Rahman M, Son M, Kim H, Lee I, Jeon H, Kim M, Kwon H, Park S, Jang J, Kim S. DHP107, a novel oral paclitaxel formulation induces less peripheral neuropathic pain and pain-related molecular alteration than intravenous paclitaxel preparation in rat. J Adv Biotechnol Exp Ther. 2019;2(2):55\u201364.","journal-title":"J Adv Biotechnol Exp Ther"},{"key":"1400_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359211061989","volume":"13","author":"S Kim","year":"2021","unstructured":"Kim S, Seo JH, Ahn J, Kim T, Kang SY, Sohn J, Yang Y, Park KH, Moon YW, Lim S, Kang MJ, Yoon KE, Cho HJ, Lee KS. Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). Ther Adv Med Oncol. 2021;13:1\u201311.","journal-title":"Ther Adv Med Oncol"},{"key":"1400_CR12","doi-asserted-by":"crossref","unstructured":"Sekiguchi K, Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull. 1961;9(11):866\u201372.","DOI":"10.1248\/cpb.9.866"},{"key":"1400_CR13","doi-asserted-by":"crossref","unstructured":"Altamimi MA, Neau SH. Investigation of the in vitro performance difference of drug-Soluplus\u00ae and drug-PEG 6000 dispersions when prepared using spray drying or lyophilization. Saudi Pharma J. 2017;25(3):419\u201339.","DOI":"10.1016\/j.jsps.2016.09.013"},{"issue":"1","key":"1400_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/jps.2600650126","volume":"65","author":"RK Reddy","year":"1976","unstructured":"Reddy RK, Khalil SA, Wafik GM. Effect of dioctyl sodium sulfosuccinate and poloxamer 188 on dissolution and intestinal absorption of sulfadiazine and sulfisoxazole in rats. J Pharm Sci. 1976;65(1):115\u20138.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1400_CR15","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.4067\/S0717-97072013000100012","volume":"58","author":"A Sharma","year":"2013","unstructured":"Sharma A, Jain CP, Tanwar YS. Preparation and characterization of solid dispersions of carvedilol with poloxamer 188. J Chil Chem Soc. 2013;58(1):1553\u20137.","journal-title":"J Chil Chem Soc"},{"issue":"3","key":"1400_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/2230-973X.160857","volume":"5","author":"A Gorajana","year":"2015","unstructured":"Gorajana A, Rajendran A, Yew L, Dua K. Preparation and characterization of cefuroxime axetil solid dispersions using hydrophilic carriers. Int J Pharm Investig. 2015;5(3):171\u20138.","journal-title":"Int J Pharm Investig"},{"issue":"5","key":"1400_CR17","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1021\/acsinfecdis.9b00231","volume":"6","author":"C Hu","year":"2020","unstructured":"Hu C, Liu Z, Liu C, Zhang Y, Fan H, Qian F. Improvement of antialveolar echinococcosis efficacy of albendazole by a novel nanocrystalline formulation with enhanced oral bioavailability. ACS Infect Dis. 2020;6(5):802\u201310.","journal-title":"ACS Infect Dis"},{"issue":"8","key":"1400_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s11095-007-9275-7","volume":"24","author":"F Qian","year":"2007","unstructured":"Qian F, Tao J, Desikan S, Hussain M, Smith RL. Mechanistic investigation of Pluronic\u00ae based nano-crystalline drug-polymer solid dispersions. Pharm Res. 2007;24(8):1551\u201360.","journal-title":"Pharm Res"},{"issue":"1","key":"1400_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijpharm.2011.01.030","volume":"407","author":"MA Mohammad","year":"2011","unstructured":"Mohammad MA, Alhalaweh A, Velaga SP. Hansen solubility parameter as a tool to predict cocrystal formation. Int J Pharm. 2011;407(1):63\u201371.","journal-title":"Int J Pharm"},{"issue":"9","key":"1400_CR20","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1002\/jps.22251","volume":"99","author":"Y Sun","year":"2010","unstructured":"Sun Y, Tao J, Zhang GGZ, Yu L. Solubilities of crystalline drugs in polymers: an improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP\/VA, and PVAc. J Pharm Sci. 2010;99(9):4023\u201331.","journal-title":"J Pharm Sci"},{"issue":"11","key":"1400_CR21","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.3109\/03639045.2015.1018275","volume":"41","author":"S Shanmugam","year":"2015","unstructured":"Shanmugam S, Im HT, Sohn YT, Kim Y, Park J, Park E, Woo JS. Enhanced oral bioavailability of paclitaxel by solid dispersion granulation. Drug Dev Ind Pharm. 2015;41(11):1864\u201376.","journal-title":"Drug Dev Ind Pharm"},{"issue":"10","key":"1400_CR22","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s11095-016-1969-2","volume":"33","author":"Y Chen","year":"2016","unstructured":"Chen Y, Wang S, Wang S, Liu C, Su C, Hageman M, Hussain M, Haskell R, Stefanski K, Qian F. Initial drug dissolution from amorphous solid dispersions controlled by polymer dissolution and drug-polymer interaction. Pharm Res. 2016;33(10):2445\u201358.","journal-title":"Pharm Res"},{"issue":"1","key":"1400_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s13346-018-0582-9","volume":"9","author":"L Miao","year":"2019","unstructured":"Miao L, Liang Y, Pan W, Gou J, Yin T, Zhang Y, He H, Tang X. Effect of supersaturation on the oral bioavailability of paclitaxel\/polymer amorphous solid dispersion. Drug Deliv Transl Res. 2019;9(1):344\u201356.","journal-title":"Drug Deliv Transl Res"},{"issue":"12","key":"1400_CR24","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1021\/js9605226","volume":"86","author":"RT Liggins","year":"1997","unstructured":"Liggins RT, Hunter WL, Burt HM. Solid-state characterization of paclitaxel. J Pharm Sci. 1997;86(12):1458\u201363.","journal-title":"J Pharm Sci"},{"key":"1400_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.msec.2019.03.002","volume":"100","author":"J Choi","year":"2019","unstructured":"Choi J, Cho NH, Kim D, Park J. Comparison of paclitaxel solid dispersion and polymeric micelles for improved oral bioavailability and in vitro anti-cancer effects. Mater Sci Eng, C. 2019;100:247\u201359.","journal-title":"Mater Sci Eng, C"},{"issue":"7","key":"1400_CR26","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1039\/C2CE06574F","volume":"14","author":"DR Weyna","year":"2012","unstructured":"Weyna DR, Cheney ML, Shan N, Hanna M, Wojtas A, Zaworotko MJ. Crystal engineering of multiple-component organic solids: pharmaceutical cocrystals of tadalafil with persistent hydrogen bonding motifs. CrystEngComm. 2012;14(7):2377\u201380.","journal-title":"CrystEngComm"},{"key":"1400_CR27","doi-asserted-by":"crossref","unstructured":"Baghel S,Cathcart H, O'Reilly NJ. Understanding the generation and maintenance of supersaturation during the dissolution of amorphous solid dispersions using modulated DSC and 1H NMR. Int J Pharm. 2018;536(1):414\u201325.","DOI":"10.1016\/j.ijpharm.2017.11.056"},{"issue":"1","key":"1400_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1021\/acs.molpharmaceut.2c00695","volume":"20","author":"D Gao","year":"2023","unstructured":"Gao D, Zhu D, Zhou X, Dong S, Chen Y. Inhomogeneous phase significantly reduces oral bioavailability of felodipine\/PVPVA amorphous solid dispersion. Mol Pharm. 2023;20(1):409\u201318.","journal-title":"Mol Pharm"},{"issue":"2","key":"1400_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1021\/mp500660m","volume":"12","author":"Y Chen","year":"2015","unstructured":"Chen Y, Liu C, Chen Z, Su C, Hageman M, Hussain M, Haskell R, Stefanski K, Qian F. Drug\u2013polymer\u2013water interaction and its implication for the dissolution performance of amorphous solid dispersions. Mol Pharm. 2015;12(2):576\u201389.","journal-title":"Mol Pharm"},{"issue":"6","key":"1400_CR30","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1021\/acs.molpharmaceut.1c00144","volume":"18","author":"S Mukesh","year":"2021","unstructured":"Mukesh S, Joshi P, Bansal AK, Kashyap MC, Mandal SK, Sathe V, Sangamwar AT. Amorphous salts solid dispersions of celecoxib: enhanced biopharmaceutical performance and physical stability. Mol Pharm. 2021;18(6):2334\u201348.","journal-title":"Mol Pharm"},{"issue":"7","key":"1400_CR31","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.22074","volume":"99","author":"F Qian","year":"2010","unstructured":"Qian F, Huang J, Hussain MA. Drug\u2013polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci. 2010;99(7):2941\u20137.","journal-title":"J Pharm Sci"},{"issue":"8","key":"1400_CR32","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1002\/jps.21650","volume":"98","author":"J Brouwers","year":"2009","unstructured":"Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549\u201372.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1400_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0939-6411(00)00076-X","volume":"50","author":"C Leuner","year":"2000","unstructured":"Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47\u201360.","journal-title":"Eur J Pharm Biopharm"},{"issue":"10","key":"1400_CR34","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/jps.20906","volume":"96","author":"HR Guzman","year":"2007","unstructured":"Guzman HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, Chen H, Moreau JP, Almarsson O, Remenar JF. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96(10):2686\u2013702.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1400_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1021\/acs.molpharmaceut.5b00837","volume":"13","author":"C Liu","year":"2016","unstructured":"Liu C, Chen Z, Chen Y, Lu J, Li Y, Wang S, Wu G, Qian F. Improving oral bioavailability of sorafenib by optimizing the \u201cspring\u201d and \u201cparachute\u201d based on molecular interaction mechanisms. Mol Pharm. 2016;13(2):599\u2013608.","journal-title":"Mol Pharm"},{"key":"1400_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jconrel.2015.06.004","volume":"211","author":"DD Sun","year":"2015","unstructured":"Sun DD, Lee PI. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers. J Control Release. 2015;211:85\u201393.","journal-title":"J Control Release"},{"issue":"8","key":"1400_CR37","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1021\/mp500298q","volume":"11","author":"DY Alakhova","year":"2014","unstructured":"Alakhova DY, Kabanov AV. Pluronics and MDR reversal: an update. Mol Pharm. 2014;11(8):2566\u201378.","journal-title":"Mol Pharm"},{"issue":"11","key":"1400_CR38","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s12272-011-1114-z","volume":"34","author":"L Ma","year":"2011","unstructured":"Ma L, Wei Y, Zhou Y, Ma X, Wu X. Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. Arch Pharm Res. 2011;34(11):1939\u201343.","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1400_CR39","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1021\/acs.molpharmaceut.0c00623","volume":"18","author":"J Catalan-Figueroa","year":"2021","unstructured":"Catalan-Figueroa J, Garcia MA, Contreras P, Boisset CB, Gonzalez PM, Fiedler JL, Perez MF, Morales JO. Poloxamer 188-coated ammonium methacrylate copolymer nanocarriers enhance loperamide permeability across Pgp-expressing epithelia. Mol Pharm. 2021;18(2):743\u201350.","journal-title":"Mol Pharm"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01400-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01400-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T15:26:38Z","timestamp":1704209198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01400-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01400-0","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"assertion":[{"value":"21 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal study protocols were approved by the Institutional Animal Care and Utilization Committee of Qinghai University, CAS (approval numbers -QHU -IPC -23041).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No human studies have been performed in this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}